Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib

Author(s):
Lankheet, N.A.G.; Desar, I.M.E.; Mulder, S.F.; Burger, D.M.; Kweekel, D.M.; Herpen, C.M.L. van; Graaf, W.T.A. van der; Erp, N.P. van
Published
2017
Publication type
Article / Letter to editor
imatinibindividualized dosingpazopanibpharmacokineticssunitinibtherapeutic drug monitoring
Date issued
2017-10-31
Language
English
Is part of
British Journal of Clinical Pharmacology (2017), Vol. 83, no. 10, p. 2195-2204
hdl
1887/116071
doi
10.1111/bcp.13327